

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

SNU-16

RRID:CVCL_0076

Type: Cell Line

Proper Citation

RRID:CVCL_0076

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0076

Proper Citation: RRID:CVCL_0076

Description: Cell line SNU-16 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Gastric adenocarcinoma

Defining Citation: [PMID:1676761](#), [PMID:2158397](#), [PMID:8806092](#), [PMID:8806095](#), [PMID:10674020](#), [PMID:14720123](#), [PMID:19956504](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23637631](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:34466148](#), [PMID:35839778](#)

Comments: Population: Korean., Part of: TCGA-110-CL cell line panel., Part of: Seoul National University (SNU) cell line collection., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: MD Anderson Cell Lines Project., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-16

Synonyms: SNU16, NCI-SNU-16

Cross References: BTO:BTO_0004987, CLO:CLO_0009095, EFO:EFO_0002344, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5974, BCRC:60212, BioGRID_ORCS_Cell_line:1018, BioSample:SAMN03473127, BioSample:SAMN10987911, cancercellines:CVCL_0076, Cell_Model_Passport:SIDM01145, ChEMBL-Cells:ChEMBL3307273, ChEMBL-Targets:ChEMBL613529, CLS:305273, Cosmic:685588, Cosmic:687558, Cosmic:737365, Cosmic:848138, Cosmic:887247, Cosmic:908446, Cosmic:921597, Cosmic:1067204, Cosmic:1090452, Cosmic:1154649, Cosmic:1187295, Cosmic:1294962, Cosmic:1528873, Cosmic:1995596, Cosmic:2069774, Cosmic:2373751, Cosmic:2443799, Cosmic:2484966, Cosmic:2646590, Cosmic:2807644, Cosmic-CLP:908446, DepMap:ACH-000581, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908446, GEO:GSM267423, GEO:GSM267430, GEO:GSM267437, GEO:GSM267444, GEO:GSM552373, GEO:GSM562407, GEO:GSM827556, GEO:GSM828829, GEO:GSM844702, GEO:GSM887611, GEO:GSM888695, GEO:GSM1237680, GEO:GSM1237705, GEO:GSM1374886, GEO:GSM1670274, IARC_TP53:306, IARC_TP53:30160, IGRhCellID:SNU16, KCLB:00016, LiGeA:CCLE_312, LINCS_LDP:LCL-1889, PharmacDB:SNU16_1446_2019, PRIDE:PXD030304, Progenetix:CVCL_0076, PubChem_Cell_line:CVCL_0076, Wikidata:Q54955122

ID: CVCL_0076

Record Creation Time: 20220427T221551+0000

Record Last Update: 20260829T235947+0000

Ratings and Alerts

No rating or validation information has been found for SNU-16.

No alerts have been found for SNU-16.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lu Y, et al. (2026) GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. Cancer research, 86(10), 2429.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. Molecular cancer therapeutics, 25(5), 814.

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. *Genome research*, 36(2), 275.

Wei D, et al. (2026) OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. *Neoplasia (New York, N.Y.)*, 73, 101279.

Zhou Y, et al. (2025) Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(21), e2415983.

Qin LN, et al. (2025) Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARYlation complex. *Molecular cell*, 85(16), 3090.

Feng Z, et al. (2025) Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts. *Cancer immunology research*, 13(8), 1160.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. *Cell reports. Medicine*, 6(9), 102350.

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. *Cell reports. Medicine*, 6(7), 102213.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.

Kim B, et al. (2024) Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. *Cancer medicine*, 13(16), e70104.

Thomas JD, et al. (2024) Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. *Molecular cancer therapeutics*, 23(4), 541.

Martins F, et al. (2024) A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. *Cancer research*, 84(6), 808.

Alva-Ruiz R, et al. (2024) YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. *FEBS open bio*, 14(11), 1873.

Ma L, et al. (2023) Discovery of a Selective and Orally Bioavailable FGFR2 Degradar for Treating Gastric Cancer. *Journal of medicinal chemistry*, 66(11), 7438.

Zhao J, et al. (2023) Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips. *EBioMedicine*, 90, 104522.

Weng W, et al. (2023) AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. *Molecular cancer therapeutics*, 22(9), 1013.

Kong C, et al. (2023) MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. *Molecular cancer therapeutics*, 22(10), 1128.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Nargund AM, et al. (2022) Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. *Cancer research*, 82(14), 2538.